Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- Conditions
- Leukemia, Myelomonocytic, ChronicMyelodysplastic Syndromes
- Interventions
- Drug: INQOVI (oral decitabine)
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT05201066
- Locations
- πΊπΈ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
πΊπΈOregon Health Sciences University, Portland, Oregon, United States
πΊπΈHuntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT05199571
- Locations
- π¨π³
Novartis Investigative Site, Tianjin, China
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT05199090
- Locations
- πΊπΈ
Novartis Investigative Site, Dallas, Texas, United States
Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment C
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT05195892
- Locations
- π¬π§
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1776
- Registration Number
- NCT05192941
- Locations
- πͺπΈ
Novartis Investigative Site, Madrid, Spain
Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data
- Conditions
- Migraine
- Interventions
- Other: Aimovig
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1839
- Registration Number
- NCT05177406
- Locations
- πΊπΈ
Novartis Investigative Site, East Hanover, New Jersey, United States
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 147
- Registration Number
- NCT05172596
- Locations
- πΊπΈ
Stanford University, Palo Alto, California, United States
πΊπΈEmory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05170724
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: IMJ995 single agent
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05168748
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- πΊπΈ
University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States
πΊπΈOklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
πΊπΈMillennium Research Clin Develop, Houston, Texas, United States